Casdin Capital’s $50 Million Series B Financing in DNA Script

Baker McKenzie advised Casdin Capital on the deal.

Casdin Capital led the oversubscribed extension of the Series B fundraising of $50 million, and also included investors: Danaher Life Sciences, Agilent Technologies, Merck KGaA, Darmstadt, Germany, M. Ventures, LSP, Bpifrance Large Venture Fund and Illumina Ventures.

Casdin Capital is an investment firm based in New York focused on the life sciences and healthcare industry.

The Baker Mckenzie team was led by Partner Berthold A. Hummel (Picture), Gautier Valdiguié (Corporate/M&A, managing associate, Paris), Matthieu Grollemund (partner, Paris), Madalina-Georgiana Asandului (associate, Paris), Guillaume Le Camus (partner, Paris), Robin Gaulier (senior associate, Paris), Jeremie Paubel (partner, Paris) and Roxane Raissi (associate, Paris).

Involved fees earner: Madalina-Georgiana Asandului – Baker McKenzie; Robin Gaulier – Baker McKenzie; Matthieu Grollemund – Baker McKenzie; Berthold Hummel – Baker McKenzie; Guillaume le Camus – Baker McKenzie; Jérémie Paubel – Baker McKenzie; Roxane Raissi – Baker McKenzie; Gautier Valdiguié – Baker McKenzie;

Law Firms: Baker McKenzie;

Clients: Casdin Capital;